Bristol Myers Squibb (BMS) has announced positive Phase 3 results for two investigational therapies targeting different diseases.
The company reported success in the Aloft-IPF study of admilparant, an LPA1 antagonist being investigated in adults with idiopathic pulmonary fibrosis (IPF), and the Action-1 trial of RYZ101, a radiopharmaceutical treatment for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Both studies achieved their primary endpoints, although questions remain about the actual level of benefit and the safety and dosing profile of admilparant.
In Aloft-IPF, the 60 mg dose of admilparant produced a statistically significant effect on forced vital capacity, a measure of lung function, at the 52nd week. However, the 120 mg dose did not achieve statistical significance, leaving uncertainty about the drug’s dose-response relationship.
BMS has not yet disclosed the detailed trial data. The company said that the overall findings support admilparant’s potential to become a first-in-class treatment with meaningful clinical benefits.
The drugmaker intends to consult with regulators about the requirements for a potential approval application. In an August research note, Guggenheim Securities analysts estimated that admilparant could represent an opportunity worth more than $5 billion across IPF and progressive pulmonary fibrosis.
According to BMS, admilparant was generally well tolerated, with adverse-event-related treatment discontinuations occurring infrequently and at rates comparable to placebo. Nevertheless, references to liver toxicity and a patient death in a recent protocol amendment had raised questions about the treatment’s safety.
Although BMS did not specifically address liver safety in its latest topline announcement, William Blair analysts said the company’s management had confirmed that a case of acute liver injury occurred among patients receiving the 120 mg dose. The analysts added that an adjudication committee had concluded the injury was unlikely to have been caused by the study treatment.
The second positive result came from Action-1, where RYZ101 met its primary goal at a planned interim analysis. Patients receiving the radiopharmaceutical experienced significantly longer progression-free survival than those treated with standard care selected by investigators. BMS plans to discuss the findings and potential regulatory next steps with the U.S. Food and Drug Administration (FDA).
Detailed efficacy figures have not yet been released for Action-1 either. On safety, BMS said the results were consistent with the therapy’s established profile.
The findings support BMS’ efforts to develop RYZ101 for patients whose gastroenteropancreatic neuroendocrine tumors progress following treatment with lutetium-177 (Lu-177)-based therapy, including Novartis’ Lutathera. Patients enrolled in Action-1 had previously experienced disease progression after Lu-177 treatment. Whereas Lu-177 emits beta radiation, RYZ101 uses actinium-225, an alpha-emitting radioisotope.
Both programs could help BMS diversify its revenue as some of its biggest products approach the final stages of their life cycles. Opdivo and Eliquis together generated more than 50% of the company’s sales in the second quarter, but U.S. market exclusivity for both is expected to face a major challenge in 2028.
BMS is also looking for stronger growth from Cobenfy, its schizophrenia treatment acquired through the $14 billion purchase of Karuna Therapeutics. The medicine has yet to deliver a substantial contribution to revenue, increasing the importance of additional products capable of supporting the company’s longer-term growth.
BMS, formally known as Bristol Myers Squibb, continues to advance its clinical development strategy across respiratory diseases and oncology. Positive Phase 3 trial results in these areas can represent important milestones, potentially bringing new treatment options closer to patients while strengthening a company’s research portfolio.
For BMS, late-stage clinical success can support regulatory submissions, expand the evidence supporting existing medicines, and demonstrate the value of investing in treatments for serious conditions. Lung disease and solid tumors represent distinct medical challenges, requiring different therapeutic approaches, clinical endpoints, and safety assessments.
The significance of any reported Phase 3 success depends on the specific medicines studied, the trial populations, the magnitude of benefit, and the full clinical data. The following overview explains why late-stage results matter, how they may influence treatment development, and what patients, healthcare professionals, and investors should watch next.
Challenges Ahead for BMS
Despite the positive announcements, several questions remain.
For admilparant, researchers will need to understand why the lower dose met the primary endpoint while the higher dose did not. The complete results will be important for assessing the consistency of the treatment effect and the appropriate dosing strategy.
